

Related U.S. Application Data

- abandoned, which is a continuation of application No. 09/696,076, filed on Oct. 25, 2000, now Pat. No. 6,656, 136.
- (60) Provisional application No. 60/163,466, filed on Oct. 25, 1999, provisional application No. 60/171,703, filed on Dec. 23, 1999.

5,383,896	A	1/1995	Gershony et al.
5,391,140	A	2/1995	Schaetzle et al.
5,391,197	A	2/1995	Burdette et al.
5,394,877	A	3/1995	Orr et al.
5,415,657	A	5/1995	Taymor-Luria
5,439,477	A	8/1995	McEwen
5,453,576	A	9/1995	Krivitski
5,454,373	A	10/1995	Koger et al.
5,454,831	A	10/1995	McEwen
5,471,988	A	12/1995	Fujio et al.
5,474,071	A	12/1995	Chapelon et al. 600/439
5,492,126	A	2/1996	Hennige et al.
5,503,152	A	4/1996	Oakley et al.
5,507,744	A	4/1996	Tay et al.
5,507,790	A	4/1996	Weiss
5,515,853	A	5/1996	Smith et al.
5,520,188	A	5/1996	Hennige et al.
5,522,878	A	6/1996	Montecalvo et al.
5,524,620	A	6/1996	Rosenschein
5,526,815	A	6/1996	Granz et al.
5,534,232	A	7/1996	Denes et al.
5,536,489	A	7/1996	Lohrmann et al.
5,553,618	A	9/1996	Suzuki et al.
5,556,415	A	9/1996	McEwen et al.
5,558,092	A	9/1996	Unger et al.
5,573,497	A	11/1996	Chapelon
5,578,055	A	11/1996	McEwen
5,584,853	A	12/1996	McEwen
5,590,657	A	1/1997	Cain et al.
5,601,526	A	2/1997	Chapelon et al.
5,607,447	A	3/1997	McEwen et al.
5,609,485	A	3/1997	Bergman et al.
5,626,601	A	5/1997	Gershony et al.
5,628,730	A	5/1997	Shapland et al.
5,630,837	A	5/1997	Crowley
5,638,823	A	6/1997	Akay et al.
5,643,179	A	7/1997	Fujimoto
5,649,954	A	7/1997	McEwen
5,655,538	A	8/1997	Lorraine et al.
5,655,539	A	8/1997	Wang et al.
5,657,760	A	8/1997	Ying et al.
5,665,073	A	9/1997	Bulow et al.
5,666,954	A	9/1997	Chapelon et al.
5,681,339	A	10/1997	McEwen et al.
5,685,307	A	11/1997	Holland et al.
5,695,493	A	12/1997	Nakajima et al.
5,697,897	A	12/1997	Buchholtz et al.
D389,574	S	1/1998	Emerson et al.
5,704,361	A	1/1998	Seward et al.
5,711,058	A	1/1998	Frey et al.
5,713,363	A	2/1998	Seward et al.
5,716,374	A	2/1998	Francesca et al.
5,720,286	A	2/1998	Chapelon et al.
5,720,287	A	2/1998	Chapelon et al.
5,726,066	A	3/1998	Choi
5,735,796	A	4/1998	Granz et al.
5,738,635	A	4/1998	Chapelon et al.
5,741,295	A	4/1998	McEwen
5,755,228	A	5/1998	Wilson et al.
5,762,066	A	6/1998	Law et al.
5,769,790	A	6/1998	Watkins et al.
5,788,636	A	8/1998	Curley
5,807,285	A	9/1998	Vaitekunas et al.
5,810,007	A	9/1998	Holupka et al.
5,810,810	A	9/1998	Tay et al.
5,817,021	A	10/1998	Reichenberger
5,823,962	A	10/1998	Schaetzle et al.
5,824,015	A	10/1998	Sawyer
5,824,277	A	10/1998	Campos
5,827,204	A	10/1998	Grandia et al.
5,827,268	A	10/1998	Laufer
5,833,647	A	11/1998	Edwards
5,840,028	A	11/1998	Chubachi et al.
5,846,517	A	12/1998	Unger
5,852,860	A	12/1998	Lorraine et al.
5,853,752	A	12/1998	Unger et al.
5,855,589	A	1/1999	McEwen et al.
5,873,828	A	2/1999	Fujio et al.
5,879,314	A	3/1999	Peterson et al.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,847,016	A	11/1974	Ziedonis
3,927,662	A	12/1975	Ziedonis
4,059,098	A	11/1977	Murdock
4,167,180	A	9/1979	Kossoff
4,197,856	A	4/1980	Northrop
4,206,763	A	6/1980	Pedersen
4,237,901	A	12/1980	Taenzler
4,273,127	A	6/1981	Auth et al.
4,315,514	A	2/1982	Drewes et al. 600/427
4,469,099	A	9/1984	McEwen
4,479,494	A	10/1984	McEwen
4,484,569	A	11/1984	Driller et al.
4,545,386	A	10/1985	Hetz et al.
4,594,895	A	6/1986	Fujii 73/599
4,601,296	A	7/1986	Yerushalmi
4,605,010	A	8/1986	McEwen
4,688,578	A	8/1987	Takano et al.
4,708,836	A	11/1987	Gain et al.
4,748,985	A	6/1988	Nagasaki
4,757,820	A	7/1988	Itoh
4,770,175	A	9/1988	McEwen
4,773,865	A	9/1988	Baldwin
4,784,148	A	11/1988	Dow et al.
4,841,979	A	6/1989	Dow et al.
4,850,363	A	7/1989	Yanagawa
4,858,613	A	8/1989	Fry et al.
4,905,672	A	3/1990	Schwarze et al.
4,913,155	A	4/1990	Dow et al.
4,929,246	A	5/1990	Sinofsky
4,931,047	A	6/1990	Broadwin et al.
4,938,216	A	7/1990	Lele
4,938,217	A	7/1990	Lele
4,957,099	A	9/1990	Hassler
5,005,579	A	4/1991	Wurster et al.
RE33,590	E	5/1991	Dory
5,026,387	A	6/1991	Thomas
5,036,855	A	8/1991	Fry et al.
5,039,774	A	8/1991	Shikinami et al.
5,042,486	A	8/1991	Pfeller et al.
5,065,742	A	11/1991	Belikan et al.
5,080,101	A	1/1992	Dory
5,080,102	A	1/1992	Dory
5,150,712	A	9/1992	Dory
5,170,790	A	12/1992	Lacoste et al.
5,178,135	A	1/1993	Uchiyama et al.
5,178,148	A	1/1993	Lacoste et al.
5,181,522	A	1/1993	McEwen
5,194,291	A	3/1993	D'Aoust et al.
5,211,160	A	5/1993	Talish et al.
5,215,680	A	6/1993	D'Arrigo
5,219,401	A	6/1993	Cathignol et al.
5,230,334	A	7/1993	Klopotek
5,230,921	A	7/1993	Waltonen et al.
5,233,994	A	8/1993	Shmulewitz
5,243,988	A	9/1993	Sieben et al.
5,254,087	A	10/1993	McEwen
5,263,957	A	11/1993	Davison
5,290,278	A	3/1994	Anderson
5,307,816	A	5/1994	Hashimoto et al.
5,311,869	A	5/1994	Okazaki
5,312,431	A	5/1994	McEwen
5,318,035	A	6/1994	Konno et al.
5,352,195	A	10/1994	McEwen
5,364,389	A	11/1994	Anderson

5,882,302	A *	3/1999	Driscoll et al.	600/371	6,522,926	B1	2/2003	Kieval et al.
5,895,356	A	4/1999	Andrus		6,548,047	B1	4/2003	Unger
5,904,659	A	5/1999	Duarte		6,551,576	B1	4/2003	Unger et al.
5,906,580	A	5/1999	Kline-Schoder et al.		6,559,644	B2	5/2003	Frondlich et al.
5,911,735	A	6/1999	McEwen		6,562,037	B2	5/2003	Paton et al.
5,919,139	A	7/1999	Lin		6,565,557	B1	5/2003	Sporri et al.
5,921,994	A	7/1999	Andreas et al.		6,576,168	B2	6/2003	Hardcastle et al.
5,922,945	A	7/1999	Allmaras et al.		6,584,360	B2	6/2003	Franciscelli et al.
5,931,786	A	8/1999	Whitmore, III et al.		6,595,934	B1	7/2003	Hissong et al.
5,931,853	A	8/1999	McEwen		6,599,256	B1	7/2003	Acker et al.
5,935,144	A	8/1999	Estabrook		6,599,288	B2	7/2003	Maguire et al.
5,935,146	A	8/1999	McEwen		6,602,251	B2	8/2003	Burbank et al.
5,935,339	A	8/1999	Henderson et al.		6,612,988	B2	9/2003	Maor et al.
5,951,476	A	9/1999	Beach		6,616,624	B1	9/2003	Kieval
5,957,849	A	9/1999	Munro		6,626,855	B1	9/2003	Weng et al.
5,964,782	A	10/1999	Lafontaine et al.		6,633,658	B1	10/2003	Dabney et al.
5,976,092	A	11/1999	Chinn		6,652,461	B1	11/2003	Levkovitz
5,979,453	A	11/1999	Savage et al.		6,656,131	B2	12/2003	Alster et al.
5,993,389	A	11/1999	Driscoll, Jr. et al.		6,656,136	B1	12/2003	Weng et al.
5,997,481	A	12/1999	Adams et al.		6,676,601	B1	1/2004	Lacoste et al.
6,007,499	A *	12/1999	Martin et al.	601/3	6,682,483	B1	1/2004	Abend et al.
6,013,031	A *	1/2000	Mendlein et al.	600/442	6,685,639	B1	2/2004	Wang et al.
6,014,473	A	1/2000	Hossack et al.		6,706,892	B1	3/2004	Ezrin et al.
6,033,506	A	3/2000	Klett		6,709,392	B1	3/2004	Salgo et al.
6,036,650	A	3/2000	Wu et al.		6,709,407	B2	3/2004	Fatemi
6,037,032	A	3/2000	Klett et al.		6,716,184	B2	4/2004	Vaezy et al.
6,039,694	A	3/2000	Larson et al.		6,719,694	B2	4/2004	Weng et al.
6,042,556	A	3/2000	Beach et al.		6,719,699	B2	4/2004	Smith
6,050,943	A	4/2000	Slayton et al.		6,726,627	B1	4/2004	Lizzi et al.
6,067,371	A	5/2000	Gouge et al.		6,735,461	B2	5/2004	Vitek et al.
6,068,596	A	5/2000	Weth et al.		6,755,789	B2	6/2004	Stringer et al.
6,071,239	A	6/2000	Cribbs et al.		6,764,488	B1	7/2004	Burbank et al.
6,071,277	A	6/2000	Farley et al.		6,846,291	B2	1/2005	Smith et al.
6,078,831	A	6/2000	Belef et al.		6,868,739	B1	3/2005	Krivitski et al.
6,083,159	A	7/2000	Driscoll, Jr. et al.		6,875,176	B2	4/2005	Mourad et al.
6,087,761	A	7/2000	Lorraine et al.		6,875,420	B1	4/2005	Quay
6,102,860	A	8/2000	Mooney		6,905,498	B2	6/2005	Hooven
6,106,463	A	8/2000	Wilk		6,932,771	B2	8/2005	Whitmore et al.
6,120,453	A	9/2000	Sharp		6,955,648	B2	10/2005	Mozayani et al.
6,128,522	A	10/2000	Acker et al.		6,978,174	B2	12/2005	Gelfand et al.
6,179,831	B1	1/2001	Bliweis		7,022,077	B2	4/2006	Mourad et al.
6,182,341	B1	2/2001	Talbot et al.		7,052,463	B2	5/2006	Peszynski et al.
6,193,660	B1	2/2001	Jackson et al.		7,063,666	B2	6/2006	Weng et al.
6,200,268	B1	3/2001	Vince et al.		7,128,711	B2	10/2006	Medan et al.
6,200,539	B1	3/2001	Sherman et al.		7,149,564	B2	12/2006	Vining et al.
6,206,843	B1	3/2001	Iger et al.		7,162,303	B2	1/2007	Levin et al.
6,213,939	B1	4/2001	McEwen		7,211,060	B1	5/2007	Talish et al.
6,217,530	B1	4/2001	Martin et al.		7,260,250	B2	8/2007	Summers et al.
6,221,015	B1	4/2001	Yock		7,285,093	B2	10/2007	Anisimov et al.
6,231,507	B1	5/2001	Zikorus et al.		7,445,599	B2	11/2008	Kelly et al.
6,233,477	B1	5/2001	Chia et al.		7,470,241	B2	12/2008	Weng et al.
6,246,156	B1	6/2001	Takeuchi et al.		7,499,748	B2	3/2009	Moffitt et al.
6,254,601	B1	7/2001	Burbank et al.		7,510,536	B2	3/2009	Foley et al.
6,259,945	B1	7/2001	Epstein et al.		7,530,958	B2	5/2009	Slayton et al.
6,261,233	B1	7/2001	Kantorovich		7,534,209	B2	5/2009	Abend et al.
6,263,551	B1	7/2001	Lorraine et al.		7,553,284	B2	6/2009	Vaitekunas
6,267,734	B1	7/2001	Ishibashi et al.		7,617,005	B2	11/2009	Demarais et al.
6,270,458	B1	8/2001	Barnea		7,620,451	B2	11/2009	Demarais et al.
6,277,077	B1	8/2001	Brisken et al.		7,628,764	B2	12/2009	Duarte et al.
6,311,692	B1 *	11/2001	Vaska et al.	128/898	7,684,865	B2	3/2010	Aldrich et al.
6,315,441	B2	11/2001	King		7,697,972	B2	4/2010	Verard et al.
6,332,089	B1	12/2001	Acker et al.		2001/0014775	A1	8/2001	Koger et al.
6,361,496	B1	3/2002	Zikorus et al.		2001/0014805	A1	8/2001	Burbank et al.
6,361,548	B1	3/2002	McEwen		2001/0032382	A1	10/2001	Lorraine et al.
6,398,792	B1	6/2002	O'Connor		2001/0041910	A1	11/2001	McEwen
6,399,149	B1	6/2002	Klett et al.		2001/0044636	A1	11/2001	Pedros et al.
6,406,759	B1	6/2002	Roth		2002/0032394	A1	3/2002	Brisken et al.
6,409,720	B1	6/2002	Hissong et al.		2002/0055736	A1	5/2002	Horn et al.
6,419,669	B1	7/2002	Frazier et al.		2002/0095164	A1	7/2002	Andreas et al.
6,425,867	B1	7/2002	Vaezy et al.		2002/0193831	A1	12/2002	Smith, III
6,425,876	B1	7/2002	Frangi et al.		2003/0009194	A1	1/2003	Saker et al.
6,432,067	B1	8/2002	Martin et al.		2003/0018255	A1	1/2003	Martin et al.
6,443,894	B1	9/2002	Sumanaweera et al.		2003/0036771	A1	2/2003	McEwen
6,453,526	B2	9/2002	Lorraine et al.		2003/0050665	A1	3/2003	Ginn
6,488,639	B1	12/2002	Ribault et al.		2003/0069569	A1	4/2003	Burdette et al.
6,491,672	B2	12/2002	Slepian et al.		2003/0114756	A1	6/2003	Li
6,494,848	B1	12/2002	Sommercorn et al.		2003/0120204	A1	6/2003	Unger et al.
6,500,133	B2	12/2002	Martin et al.		2003/0153849	A1	8/2003	Huckle et al.
6,520,915	B1	2/2003	Lin et al.		2003/0195420	A1	10/2003	Mendlein et al.

2003/0208101	A1	11/2003	Cecchi	2009/0306644	A1	12/2009	Mayse et al.
2003/0216792	A1	11/2003	Levin et al.	2009/0326379	A1	12/2009	Daigle et al.
2004/0002654	A1	1/2004	Davidson et al.	2010/0092424	A1	4/2010	Sanghvi et al.
2004/0030227	A1	2/2004	Littrup et al.	2010/0125269	A1	5/2010	Emmons et al.
2004/0030268	A1	2/2004	Weng et al.	2010/0174188	A1	7/2010	Wang et al.
2004/0054287	A1	3/2004	Stephens	2011/0028867	A1	2/2011	Choo et al.
2004/0054289	A1	3/2004	Eberle et al.	2011/0118602	A1	5/2011	Weng et al.
2004/0078034	A1	4/2004	Acker et al.	2011/0178403	A1	7/2011	Weng et al.
2004/0078219	A1	4/2004	Kaylor	2011/0178445	A1	7/2011	Weng et al.
2004/0082978	A1	4/2004	Harrison et al.	2011/0230763	A1	9/2011	Emery et al.
2004/0097840	A1	5/2004	Holmer	2011/0230796	A1	9/2011	Emery et al.
2004/0106880	A1	6/2004	Weng et al.				
2004/0113524	A1	6/2004	Baumgartner et al.				
2004/0122493	A1	6/2004	Ishibashi et al.				
2004/0127798	A1	7/2004	Dala-Krishna et al.				
2004/0153126	A1	8/2004	Okai				
2004/0158154	A1	8/2004	Hanafy et al.				
2004/0234453	A1	11/2004	Smith				
2004/0254620	A1	12/2004	Lacoste et al.				
2004/0267252	A1	12/2004	Washington et al.				
2005/0043625	A1	2/2005	Oliver et al.				
2005/0046311	A1	3/2005	Baumgartner et al.				
2005/0054955	A1	3/2005	Lidgren				
2005/0065436	A1	3/2005	Ho et al.				
2005/0070790	A1	3/2005	Niwa et al.				
2005/0085793	A1	4/2005	Glossop				
2005/0090104	A1	4/2005	Yang et al.				
2005/0096542	A1	5/2005	Weng et al.				
2005/0124884	A1	6/2005	Bolorforosh et al.				
2005/0154299	A1	7/2005	Hocor et al.				
2005/0165298	A1	7/2005	Larson et al.				
2005/0182297	A1	8/2005	Gravenstein et al.				
2005/0182319	A1	8/2005	Glossop				
2005/0240102	A1	10/2005	Rachlin et al.				
2005/0240103	A1	10/2005	Byrd et al.				
2005/0240126	A1	10/2005	Foley et al.				
2005/0240170	A1	10/2005	Zhang et al.				
2006/0025756	A1	2/2006	Francischelli et al.				
2006/0058678	A1	3/2006	Vitek et al.				
2006/0122514	A1	6/2006	Byrd et al.				
2006/0184069	A1	8/2006	Vaitekunas				
2006/0235300	A1	10/2006	Weng et al.				
2007/0004984	A1	1/2007	Crum et al.				
2007/0055155	A1	3/2007	Owen et al.				
2007/0106339	A1	5/2007	Errico et al.				
2007/0129720	A1	6/2007	Demarais et al.				
2007/0142879	A1	6/2007	Greenberg et al.				
2007/0149880	A1	6/2007	Willis				
2007/0167806	A1	7/2007	Wood et al.				
2007/0179379	A1	8/2007	Weng et al.				
2007/0213616	A1	9/2007	Anderson et al.				
2007/0233185	A1	10/2007	Anderson et al.				
2007/0239000	A1	10/2007	Emery et al.				
2007/0265687	A1	11/2007	Deem et al.				
2008/0033292	A1	2/2008	Shafran				
2008/0039746	A1	2/2008	Hissong et al.				
2008/0045864	A1	2/2008	Candy et al.				
2008/0045865	A1	2/2008	Kislev				
2008/0047325	A1	2/2008	Bartlett				
2008/0200815	A1	8/2008	Van Der Steen et al.				
2008/0234569	A1	9/2008	Tidhar et al.				
2008/0255498	A1	10/2008	Houle				
2008/0255642	A1	10/2008	Zarins et al.				
2008/0312561	A1	12/2008	Chauhan				
2008/0317204	A1	12/2008	Sumanaweera et al.				
2008/0319375	A1	12/2008	Hardy				
2009/0012098	A1	1/2009	Jordan et al.				
2009/0036948	A1	2/2009	Levin et al.				
2009/0054770	A1	2/2009	Daigle				
2009/0062697	A1	3/2009	Zhang et al.				
2009/0062873	A1	3/2009	Wu et al.				
2009/0076409	A1	3/2009	Wu et al.				
2009/0088623	A1	4/2009	Vortman et al.				
2009/0112095	A1	4/2009	Daigle				
2009/0112133	A1	4/2009	Deisseroth et al.				
2009/0163982	A1	6/2009	deCharms				
2009/0221939	A1	9/2009	Demarais et al.				
2009/0247911	A1	10/2009	Novak et al.				
2009/0264755	A1	10/2009	Chen et al.				

FOREIGN PATENT DOCUMENTS

DE	102 09 380	9/2003
EP	0 225 120	6/1987
EP	0 239 999	10/1987
EP	0 383 270	8/1990
EP	0420758	4/1991
EP	0 679 371	11/1995
EP	1 219 245	7/2002
EP	1265223	12/2002
EP	1 449 583	8/2004
EP	1874192	A1 10/2006
EP	2181342	A1 2/2009
EP	2303131	12/2009
FR	2672486	8/1992
WO	WO 9731364	8/1997
WO	WO 98/11840	3/1998
WO	WO 98/58588	12/1998
WO	WO 99/07432	2/1999
WO	WO 99/22652	5/1999
WO	WO 99/48621	9/1999
WO	WO 0072919	12/2000
WO	WO 01/34018	5/2001
WO	WO 02069805	9/2002
WO	WO 2004/064598	8/2004
WO	WO 2004/086086	10/2004
WO	WO 2005/030295	4/2005
WO	WO 2005/056105	6/2005
WO	WO 2006/113445	10/2006
WO	WO 2007/073551	6/2007
WO	WO 2009/026534	2/2009
WO	WO 2009/158399	12/2009
WO	WO 01/53757	5/2011
WO	WO 2011/053757	5/2011
WO	WO 2011/053772	5/2011

OTHER PUBLICATIONS

Mughal et al., Assessment of Bone Status Using the Contact Ultrasound Bone Analyser, Archives of Disease in Childhood, 1997, p. 535-536.*

Accord et al., "The Issue of Transmurality in Surgical Ablation for Atrial Fibrillation." Cardiothoracic Surgery Network: 3pp, Feb. 8, 2007.

Amenta et al., "A New Voronoi-Based Surface Reconstruction Algorithm." Computer Graphics: 7pp, 1998.

American Red Cross., "Blood 101." 4pp., Dec. 11, 2007.

Anand et al., "Monitoring formation of high intensity focused ultrasound (HIFU) induced lesions using backscattered ultrasound." Acoustical Society of America; Mar. 10, 2004.

Anand et al., "Using the ATL 1000 to Collect Domodulated RF Data for Monitoring HIFU Lesion Formation." Presented at SPIE Medical Imaging 2003. 11pp, 2003.

Aurenhammer, F. "Voronoi diagrams—A Survey of a Fundamental Geometric Data Structure." ACM Computing Surveys, vol. 23, No. 3: 345-405, Sep. 1991.

Bachmann et al., "Targeting Mucosal Addressin Cellular Adhesion Molecule (MAdCAM)-1 to Noninvasively Image Experimental Crohn's Disease." Gastroenterology; vol. 130: 8-16, 2006.

Barthe et al., "Efficient Wideband Linear Arrays for Imaging and Therapy" IEEE Ultrasonics Symposium. pp. 1249-1252 (1999).

Bauer et al., "Ultrasound Imaging with SonoVue: Low Mechanical Index Real-Time Imaging." Acad. Radiol.; vol. 9, Suppl. 2: S282-S284, 2002.

Beard et al., "An Annular Focus Ultrasonic Lens for Local Hyperthermia Treatment of Small Tumors." Ultrasound in

- Medicine & Biology; vol. 8, No. 2: 177-184, 1982.
- Bokarewa et al., "Tissue factor as a proinflammatory agent." *Arthritis Research*, vol. 4: 190-195, Jan. 10, 2002.
- Bots et al., "Intima Media Thickness as a Surrogate Marker for Generalised Atherosclerosis." *Cardiovascular Drugs and Therapy*, ProQuest Medical Library; vol. 16, No. 4: 341-351, Jul. 2002.
- Brayman et al., "Erosion of Artificial Endothelia In Vitro by Pulsed Ultrasound: Acoustic Pressure, Frequency, Membrane Orientation and Microbubble Contrast Agent Dependence." *Ultrasound in Medicine & Biology*; vol. 25, No. 8: 1305-1320, 1999.
- Buller et al., "Accurate Three-dimensional Wall Thickness Measurement From Multi-Slice Short-Axis MR Imaging." *Computers in Cardiology*, 245-248, 1995.
- Byram et al., "3-D Phantom and In Vivo Cardiac Speckle Tracking Using a Matrix Array and Raw Echo Data." *IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control*, vol. 57, No. 4: 839-854, Apr. 2010.
- Campese, V., Krol, E. Neurogenic Factors in Renal Hypertension. *Current Hypertension Reports* 2002, 4:256-260.
- Canadian Examination Report dated Nov. 14, 2007 in CA Patent Application 2,387,127, filed Oct. 25, 2000.
- Chao et al., "Aspheric lens design." *Ultrasonics Symposium*, 2000 IEEE, vol. 2: Abstract Only, Oct. 2000.
- Chelule et al., "Fabrication of Medical Models From Scan Data via Rapid Prototyping Techniques." 9 pp., Feb. 7, 2007.
- Chen et al., "A comparison of the fragmentation thresholds and inertial cavitation doses of different ultrasound contrast agents." *Journal of the Acoustical Society of America*, vol. 113, No. 1: 643-665, Jan. 2003.
- Chen et al., "Inertial Cavitation Dose and Hemolysis Produced In Vitro With or Without Optison." *Ultrasound in Medicine & Biology*, vol. 29, No. 5: 725-737, 2003.
- Chen et al., DC-Biased Electrostrictive Materials and Transducers for Medical Imaging, 1997 IEEE Ultrasonics Symposium, IEEE, Aug. 1997.
- Chong et al., "Tissue Factor and Thrombin Mediate Myocardial Ischemia-Reperfusion Injury." *The Society of Thoracic Surgeons*, vol. 75: S649-655, 2003.
- Damianou, et al., "Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery", *IEEE Ultrasonic Symposium*, (1993) 1199-1202.
- Dayton et al., "The magnitude of radiation force on ultrasound contrast agents." *Journal of the Acoustical Society of America*, vol. 112, No. 5, Part 1: 2183-2192, Nov. 2002.
- Dempsy et al., "Thickness of Carotid Artery Atherosclerotic Plaque and Ischemic Risk." *Neurosurgery*, vol. 27, No. 3: 343-348, 1990.
- Dewhirst, et al., "Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia", *Int. J. Hyperthermia*, (2003) 19(3):267-294.
- Dibona, G. F., et al., Chaotic behavior of renal sympathetic nerve activity: effect of baroreceptor denervation and cardiac failure, *Am J Physiol Renal Physiol*, 279:F491-501, 2000.
- Dibona, G.F.: "Neural control of the kidney: functionally specific renal sympathetic nerve fibers." *Am J. Physiol Regulatory Integrative Comp Physiol* 279: R1517-1524, 2000.
- Dibona, GF. Functionally Specific Renal Sympathetic Nerve Fibers: Role in Cardiovascular Regulation. *American Journal of Hypertension*. 2001 vol. 14(6) 163S-170S.
- Doumas, M., et al., Renal Sympathetic Denervation: The Jury is Still Out, *The Lancet*, Nov. 2010, vol. 376, Issue 9756, pp. 1878-1880.
- Ebbini et al., "Image-guided noninvasive surgery with ultrasound phased arrays." *SPIE*, vol. 3249: 230-239, Apr. 2, 1998.
- Edelsbrunner, Herbert. "Geometry and Topology for Mesh Generation." Cambridge University Press: 68pp, 2001.
- Esler, Murray D., et al., Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial, *The Lancet*, vol. 376, Issue 9756, pp. 1903-1909.
- European Examination Report dated Mar. 7, 2008 in EP Patent Application 989717.4, filed Oct. 25, 2000.
- Everbach et al., "Cavitational Mechanisms in Ultrasound-Accelerated Thrombolysis at 1 MHz." *Ultrasound in Medicine & Biology*, vol. 26, No. 7: 1153-1160, 2000.
- Ewert et al., "Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells." *Kidney International*, vol. 41: 375-383, 1992.
- Fjfield et al.; "A parametric study of the concentric-ring transducer design for MRI guided ultrasound surgery." *J. Acoust. Soc. Am* 100 (2) Pt. 1, Aug. 1996.
- Ganapathy et al., "A New General Triangulation Method for Planar Contours." *Computer Graphics* vol. 16, No. 3:69-75, 1982.
- Grassi, G. Role of the Sympathetic Nervous System in Human Hypertension. *Journal of Hypertension*. 1998, 16: 1979-1987.
- Gray, Henry. "The Skull." *Anatomy of the Human Body*: 7pp., 1918.
- Guzman et al., "Ultrasound—Mediated Disruption of Cell Membranes. I. Quantification of Molecular uptake and Cell Viability. / II. Heterogeneous effects on cells." *Journal of the Acoustical Society of America*, vol. 110, No. 1: 588-606, Jul. 2001.
- Hachimine, K. et al. Sonodynamic Therapy of Cancer Using a Novel Porphyrin Derivative, DCPH-P-Na(I), which is Devoid of Photosensitivity. *Cancer Science* 2007; 98: 916-920.
- Hadimioglu et al., "High-Efficiency Fresnel Acoustic Lenses." *Ultrasonics Symposium* 1993 IEEE: 579-582, 1993.
- Han et al., "A Fast Minimal Path Active Contour Model." *IEEE Transactions on Image Processing*, vol. 10, No. 6: 865-873, Jun. 2001.
- Hatangadi, Ram. "A Novel Dual Axis Multiplanar Transesophageal Ultrasound Probe for Three-Dimensional Echocardiograph." University of Washington, Department of Sciences and Engineering, vol. 55-11B: Abstract 1pg, 1994.
- Holt et al., "Bubbles and Hifu: the Good, the Bad and the Ugly." Boston University, Department of Aerospace and Mechanical Engineering: 120-131, 2002.
- Hubka et al., "Three-dimensional echocardiographic measurement of left ventricular wall thickness: In vitro and in vivo validation." *Journal of the American Society of Echocardiography*, vol. 15, No. 2: 129-135, 2002.
- Hutchinson et al. "Intracavitary Ultrasound Phased Arrays for Noninvasive Prostate Surgery." *IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control*. 43(6):1032-1042 (1996).
- Hwang et al., "Vascular Effects Induced by Combined 1-MHz Ultrasound and Microbubble Contrast Agent Treatments In Vivo." *Ultrasound in Medicine & Biology*, vol. 31, No. 4: 553-564, 2005.
- Hynynen et al., "Potential Adverse Effects of High-Intensity Focused Ultrasound Exposure on Blood Vessels In Vivo." *Ultrasound in Medicine & Biology*, vol. 22, No. 2: 193-201, 1996.
- Iannuzzi et al., "Ultrasonographic Correlates of Carotid Atherosclerosis in Transient Ischemic Attack and Stroke." *Stroke*, ProQuest Medical Library, vol. 26, No. 4: 614-619, 1995.
- Idell et al., "Fibrin Turnover in Lung Inflammation and Neoplasia." *American Journal of Respiratory and Critical Care Medicine*, vol. 163: 578-584, 2001.
- Indman, Paul. "Alternatives in Gynecology." *Hysteroscopy*, OBGYN.net, Oct. 14, 2004. <http://www.gynalternatives.com/hsc.html>.
- International Preliminary Report on Patentability dated Jun. 5, 2003 for PCT Application No. PCT/US00/35262.
- International Search Report and Written Opinion dated Apr. 23, 2001 for PCT Application No. PCT/US00/35262.
- International Search Report and Written Opinion dated Aug. 4, 2005 for PCT Application No. PCT/US2005/001893.
- International Search Report and Written Opinion dated Jul. 11, 2007 for PCT Application No. PCT/US2006/041163.
- International Search Report and Written Opinion dated Jun. 30, 2008 for PCT Application No. PCT/US2007/087310.
- International Search Report and Written Opinion dated Mar. 30, 2007 for Application No. PCT/US2006/027688 filed on Jul. 13, 2006.
- International Search Report and Written Opinion dated May 18, 2001 for PCT Application No. PCT/US00/41606.
- International Search Report and Written Opinion dated May 29, 2007 for PCT Application No. PCT/US04/31506.
- Invitation to Pay Additional Fees and Partial International Search Report dated Nov. 29, 2006 for PCT Application No. PCT/US2006/027688.
- Janssen, BJ and Smits, J. Renal Nerves in Hypertension. *Mineral and Electrolyte Metabolism*. 1090; 15:74-82, 1989.

- Jolesz, F. MRI-Guided Focused Ultrasound Surgery. *Annual Review of Medicine*. 2009 60: 417-30.
- Kaczkowski et al., "Development of a High Intensity Focused Ultrasound System for Image-Guided Ultrasonic Surgery." *Ultrasound for Surgery*, Oct. 14, 2004. (<http://cimu.apl.washington.edu/hifusurgerysystem.html>).
- Kang et al., "Analysis of the Measurement Precision of Arterial Lumen and Wall Areas Using High-Resolution MRI." *Magnetic Resonance in Medicine*, vol. 44: 968-972, 2000.
- Klibanov et al., "Detection of Individual Microbubbles of an Ultrasound contrast Agent: Fundamental and Pulse Inversion Imaging." *Academy of Radiology*, vol. 9, Suppl. 2: S279-S281, 2002.
- Kojima, T., Matrix Array Transducer and Flexible Matrix ARRAY Transducer, Proceedings of the Ultrasonics Symposium, vol. 2:649-653 (1986).
- Krum, H et. al. Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: a Multicentre Safety and Proof-of-Principle Cohort Study. *Lancet* 2009 373; 1275-81.
- Krum, H. et. al. Pharmacologic Management of the Cardiorenal Syndrome in Heart Failure. *Current Heart Failure Reports* 2009, 6: 105-111.
- Kudo et al., "Study on Mechanism of Cell Damage Caused by Microbubbles Exposed to Ultrasound." *Ultrasound in Medicine & Biology*, vol. 29, Supplement: 4pp, 2003.
- Lalonde et al., "Field conjugate acoustic lenses for ultrasound hyperthermia." *Ultrasonics, Ferroelectrics and Frequency Control*, IEEE Transactions, vol. 40, Issue 5: Abstract 1 pg., Sep. 1993.
- Martin et al., Hemostasis of Punctured Vessels Using Doppler-Guided High Intensity Ultrasound, *Ultrasound in Med.& Biol.*, vol. 25, pp. 985-990, 1999, USA.
- Meyers, D. "Multiresolution tiling." *Computer Graphics*, No. 5: 325-340, 1994.
- Miller et al., "A Review of In Vitro Bioeffects of Inertial Ultrasonic Cavitation From a Mechanistic Perspective." *Ultrasound in Medicine & Biology*, vol. 22, No. 9: 1131-1154, 1996.
- Miller et al., "Diagnostic ultrasound activation of contrast agent gas bodies induces capillary rupture in mice." *PNAS*, vol. 97, No. 18: 10179-10184, 2000.
- Moss, Nicholas G. Renal Function and Renal Afferent and Efferent Nerve Activity. *American Journal Physiology*. 243 (Renal Fluid Electrolyte Physiology) 12: F425-F433, 1982.
- n. a., "Breast Cancer—Insightec: focused ultrasound for non invasive treatment." FAQ, Oct. 14, 2004. (http://www.exablate2000.com/physicians_faq.html).
- n. a., "Cavitation." *Ultrasound TIP—U.S. Database*: Dec. 12, 2007.
- n. a., "Mechanical Bioeffects in the Presence of Gas-Carrier Ultrasound Contrast Agents." *Journal of Ultrasound & Medicine*, vol. 19: 120-142, 2000.
- Ng et al., "Therapeutic Ultrasound: Its Application in Drug Delivery." *Medicinal Research Reviews*, vol. 22, No. 2: 204-233, 2002.
- Notice of Allowance dated Mar. 25, 2003 from U.S. Appl. No. 09/696,076, filed Oct. 25, 2000.
- Office Action dated Apr. 29, 2011 for U.S. Appl. No. 12/202,195.
- Office Action dated Apr. 6, 2010 for U.S. Appl. No. 11/619,996.
- Office Action dated Aug. 17, 2006 from U.S. Appl. No. 10/671,417, filed Sep. 24, 2003.
- Office Action dated Feb. 18, 2011 for U.S. Appl. No. 11/583,656.
- Office Action dated Jan. 7, 2011 for U.S. Appl. No. 12/762,938.
- Office Action dated Jul. 14, 2009 for U.S. Appl. No. 11/619,996.
- Office Action dated Jul. 31, 2007 from U.S. Appl. No. 10/671,417, filed Sep. 24, 2003.
- Office Action dated Jul. 5, 2006 for U.S. Appl. No. 10/616,831.
- Office Action dated Jul. 9, 2008 for U.S. Appl. No. 11/486,528.
- Office Action dated Jun. 28, 2010 for U.S. Appl. No. 12/247,969.
- Office Action dated Mar. 18, 2011 for U.S. Appl. No. 12/247,969.
- Office Action dated Mar. 4, 2011 for U.S. Appl. No. 11/583,569.
- Office Action dated Nov. 16, 2010 for U.S. Appl. No. 12/202,195.
- Office Action dated Nov. 29, 2002 from U.S. Appl. No. 09/696,076, filed Oct. 25, 2000.
- Office Action dated Oct. 19, 2009 for U.S. Appl. No. 11/486,526.
- Office Action dated Oct. 19, 2009 for U.S. Appl. No. 11/583,256.
- Office Action dated Sep. 16, 2010 for U.S. Appl. No. 11/583,656.
- O'Leary et al., "Carotid-artery Intima and Media Thickness as a Risk Factor for Myocardial Infarction and Stroke in Older Adults." *Cardiovascular Health Study Collaborative Research Group. New England Journal of Medicine*, vol. 340, No. 1: 14-22, Jan. 7, 1999.
- Ostensen et al., "Characterization and Use of Ultrasound Contrast Agents." *Academy of Radiology*, vol. 9, Suppl. 2: S276-S278, 2002.
- Owaki et al., "The Ultrasonic Coagulating and Cutting System Injuries Nerve Function." *Endoscopy*, vol. 34, No. 7: 575-579, 2002.
- Pernot, et al., "Temperature Estimation Using Ultrasonic Spatial Compound Imaging", *IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control*, (May 2004) 51(5):606-615.
- Pignoli et al., "Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging." *Circulation*, vol. 74, No. 6:1399-1406, Dec. 1986.
- Poliachik et al., "Activation, Aggregation and Adhesion of Platelets Exposed to High-Intensity Focused Ultrasound." *Ultrasound in Medicine & Biology*, vol. 27, No. 11: 1567-1576, 2001.
- Poliachik et al., "Effect of High —Intensity Focused Ultrasound on Whole Blood With or Without Microbubble Contrast Agent." *Ultrasound in Medicine & Biology*, vol. 25, No. 6: 991-998, 1999.
- Porter et al., "Ultrasound, Microbubbles and Thrombolysis." *Progress in Cardiovascular Diseases*, vol. 44, No. 2: 101-110, Oct. 2001.
- Recchia et al., Ultrasonic Tissue Characterization of Blood during Stasis and Thrombosis with a Real-Time Linear-Array Backscatter Imaging System., *Coronary Artery Disease*, 1993, 4:987-994.
- Rivens et al., "Vascular Occlusion Using Focused Ultrasound Surgery for Use in Fetal Medicine." *European Journal of Ultrasound*, vol. 9: 89-97, 1999.
- Rose, Joseph, "Source Influence" *Ultrasonic Waves in Solid Media*, pp. 200-227, Cambridge University Press, 1999, USA.
- Rosen et al., "Vascular Occlusive Diseases." 37pp., revised 2002.
- Rosenschein et al., "Shock-Wave Thrombus Ablation, A New Method for Noninvasive Mechanical Thrombolysis." *The American Journal of Cardiology*, vol. 70, Issue 15: Abstract, Nov. 15, 1992.
- Rosenschein et al., "Ultrasound Imaging-Guided Noninvasive Ultrasound Thrombolysis—Preclinical Results." *Circulation*, vol. 102: 238-245, 2000. (<http://www.circulationaha.com.org>).
- Sanghvi et al. "High-Intensity Focused Ultrasounds." *Experimental and Investigational Endoscopy*. 4(2):383-395 (1994).
- Schlaich, MP. Sympathetic Activation in Chronic Renal Failure. *Journal American Society Nephrology* 20: 933-939, 2009.
- Schulte-Altendorfer et al., "Accuracy of In Vivo Carotid B-Mode Ultrasound Compared with Pathological Analysis: Intima-Media Thickening, Lumen Diameter, and Cross-Sectional Area." *Stroke*, vol. 32, No. 7: 1520-1524, 2001.
- Sheahan et al., Observing the Bracial Artery through a Pressure Cuff, *Physiol. Meas.* 14 (1993) 1-6.
- Sherit et al., The Characterisation and Modelling of Electrostrictive Ceramics for Transducers, *Ferroelectrics*, 228:(1-4), pp. 167-196, 1999.
- Shrout et al., Classification of Electrostrictive-Based Materials for Transducers, 1993.
- Shung, et al., "Ultrasonic Characterization of Blood During Coagulation", *J. Clin. Ultrasound*, (1984) 12:147-153.
- Simon, et al, "Two-Dimensional Temperature Estimation Using Diagnostic Ultrasound", *IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control*, (Jul. 1998) 45(4):1088-1099.
- Tachibana et al., "Albumin Microbubble Echo-Contrast Material as an Enhancer for Ultrasound Accelerated Thrombolysis." *Circulation*, vol. 92: 1148-1150, 1995.
- Tachibana et al., "The Use of Ultrasound for Drug Delivery." *Echocardiography*, vol. 18, No. 4: 323-328, May 2001.
- Tardy et al., "In Vivo Ultrasound Imaging of Thrombi Using a Target-specific Contrast Agent." *Academy of Radiology*, vol. 9, Suppl. 2: S294-S296, 2002.
- ter Haar, G. "Ultrasound Focal Beam Surgery." *Ultrasound in Medicine and Biology*. 21(9):1089-1100 (1995).
- Vaezy et al., "Hemostasis of Punctured Blood Vessels Using High Intensity Focused Ultrasound," *Ultrasound in Med.& Biol.*, vol. 24, No. 6, pp. 903-910, 1998, USA.

- Vaezy et al., "Acoustic surgery." *Physics World*: 35-39, Aug. 2001.
- Vaezy et al., "Hemostasis and Tumor Treatment using High Intensity Focused Ultrasound: Experimental Investigations and Device Development." *First International Workshop on the Application of HIFU in Medicine*: 46-49, 2001.
- Vaezy et al., "Hemostasis using high intensity focused ultrasound." *European Journal of Ultrasound*, vol. 9: 79-87, 1999.
- Vaezy et al., "Intra-operative acoustic hemostasis of liver: production of a homogenate for effective treatment." *Ultrasonics*, vol. 43: 265-269, 2005.
- Vaezy et al., "Use of High-Intensity Focused Ultrasound to Control Bleeding," *Mar. 1999, J Vasc Surg*, vol. 29, pp. 533-542.
- Valente, JF et. al. *Laparoscopic Renal Denervation for Intractable ADPKD Related Pain. Nephrology Dialysis and Transplantation*. 2001 16:160.
- Von Land et al., "Development of an Improved Centerline Wall Motion Model." *IEEE*: 687-690, 1991.
- Watkin et al., "Multi-Modal Contrast Agents: A First Step." *Academy of Radiology*, vol. 9, Suppl. 2: S285-S287, 2002.
- Wickline et al., "Blood Contrast Enhancement with a Novel, Non-Gaseous Nanoparticle Contrast Agent." *Academy of Radiology*, vol. 9, Suppl. 2: S290-S293, 2002.
- Williamson et al., "Color Doppler Ultrasound Imaging of the Eye and Orbit." *Survey of Ophthalmology*, vol. 40, No. 4: 255-267, 1996.
- Yu et al., "A microbubble agent improves the therapeutic efficiency of high intensity focused ultrasound: a rabbit kidney study." *Urological Research, PubMed: Abstract*, 2004.
- Office Action dated Dec. 30, 2011 for U.S. Appl. No. 12/896,740.
- Office Action dated Dec. 15, 2011 for U.S. Appl. No. 13/026,108.
- Office Action dated Dec. 8, 2011 for U.S. Appl. No. 11/955,310.
- Office Action dated Nov. 30, 2011 for U.S. Appl. No. 13/011,533.
- Office Action dated Oct. 25, 2011 for U.S. Appl. No. 13/025,959.
- Takeuchi et al., Dec. 4, 1990, *Relaxor ferroelectric transducers*, *IEEE Ultrasonics Symposium*, pp. 697-705.
- Final Office Action dated Jun. 5, 2012 for U.S. Appl. No. 12/896,740.
- Final Office Action dated May 14, 2012 for U.S. Appl. No. 12/026,108.
- Office Action dated Feb. 3, 2012 for U.S. Appl. No. 13/245,689.
- Final Office Action dated Jun. 13, 2012 for U.S. Appl. No. 13/245,689.
- Office Action dated Jun. 7, 2012 for U.S. Appl. No. 13/344,418.
- Office Action dated Jun. 11, 2012 for U.S. Appl. No. 13/346,466.
- Office Action dated Jul. 10, 2012 for U.S. Appl. No. 12/951,850.
- Final Office Action dated May 10, 2012 for U.S. Appl. No. 11/583,656.
- Office Action dated May 24, 2012 for U.S. Appl. No. 13/118,144.
- First Action Interview Office Action Summary dated May 30, 2012 for U.S. Appl. No. 13/245,703.
- Office Action dated Apr. 6, 2012 for U.S. Appl. No. 12/685,655.
- Office Action dated Apr. 10, 2012 for U.S. Appl. No. 12/725,450.
- International Search Report and Written Opinion dated Jul. 27, 2011 for PCT Application No. PCT/US2011/033337.
- International Search Report and Written Opinion dated Jun. 6, 2011 for PCT Application No. PCT/US2010/052197.
- Office Action dated Mar. 20, 2012 for U.S. Appl. No. 13/246,775.
- Office Action dated Nov. 28, 2011 for U.S. Appl. No. 13/246,763.
- International Search Report and Written Opinion dated Dec. 6, 2010 for PCT Application No. PCT/US2010/052193.
- Office Action dated Nov. 2, 2012 for U.S. Appl. No. 12/896,740.
- Office Action dated Oct. 25, 2012 for U.S. Appl. No. 13/245,689.
- Office Action dated Dec. 10, 2012 for U.S. Appl. No. 13/344,418.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3






FIG. 4






FIG. 6




FIG. 6A




FIG. 7






FIG. 7A






FIG. 8




FIG. 8A




FIG. 9




FIG. 10

FIG. 10A






FIG. 11



METHODS AND APPARATUS FOR FOCUSED ULTRASOUND APPLICATION

RELATED APPLICATIONS

This application is a continuation of co-pending U.S. application Ser. No. 12/896,740, filed Oct. 1, 2010, which is a continuation of co-pending U.S. application Ser. No. 11/619,996, filed Jan. 4, 2007, which is a continuation of U.S. application Ser. No. 10/616,831, filed Jul. 10, 2003, which is a continuation of U.S. application Ser. No. 09/696,076, filed Oct. 25, 2000, now U.S. Pat. No. 6,656,136, which claims the benefit of U.S. provisional patent application Ser. No. 60/163,466, filed Oct. 25, 1999, and U.S. provisional patent application Ser. No. 60/171,703, filed Dec. 23, 1999.

FIELD OF THE INVENTION

The present invention generally relates to methods and apparatus for sealing vascular punctures and wounds, and more particularly, to a device that may be used to deliver ultrasound energy to a vascular puncture site to arrest bleeding.

BACKGROUND OF THE INVENTION

Various surgical procedures are performed by medical specialists such as cardiologists and radiologists, utilizing percutaneous entry into a blood vessel. To facilitate cardiovascular procedures, a small gauge needle is introduced through the skin and into a target blood vessel, often the femoral artery. The needle forms a puncture through the blood vessel wall at the distal end of a tract that extends through the overlying tissue. A guide wire is then introduced through the bore of the needle, and the needle is withdrawn over the guide wire. An introducer sheath is next advanced over the guide wire; the sheath and guide wire are left in place to provide access during subsequent procedure(s). The sheath facilitates passage of a variety of diagnostic and therapeutic instruments and devices into the vessel and its tributaries. Illustrative diagnostic procedures include angiography, intravascular ultrasonic imaging, and the like; exemplary interventional procedures include angioplasty, atherectomy, stent and graft placement, embolization, and the like. After this procedure is completed, the catheters, guide wire, and introducer sheath are removed, and it is necessary to close the vascular puncture to provide hemostasis and allow healing.

The most common technique for achieving hemostasis is to apply hard pressure on the patient's skin in the region of the tissue tract and vascular puncture to form a blood clot. Initially, pressure is applied manually and subsequently is maintained through the use of mechanical clamps and other pressure-applying devices. While effective in most cases, the application of external pressure to the patient's skin presents a number of disadvantages. When applied manually, the procedure is time-consuming and requires the presence of a medical professional for thirty minutes or more. For both manual and mechanical pressure application, the procedure is uncomfortable for the patient and frequently requires the administration of analgesics to be tolerable. Moreover, the application of excessive pressure can occlude the underlying artery, resulting in ischemia and/or thrombosis. Even after hemostasis has apparently been achieved, the patient must remain immobile and under observation for hours to prevent dislodgment of the clot and to assure that bleeding from the puncture wound does not resume. Renewed bleeding through the tissue tract is not uncommon and can result in hematoma,

pseudoaneurisms, and arteriovenous fistulas. Such complications may require blood transfusion, surgical intervention, or other corrective procedures. The risk of these complications increases with the use of larger sheath sizes, which are frequently necessary in interventional procedures, and when the patient is anticoagulated with heparin or other drugs.

In recent years, several hemostasis techniques have been proposed to address the problem of sealing vessel wall punctures following percutaneous transcatheter procedures. Related prior art is described in U.S. Pat. Nos. 5,320,639; 5,370,660; 5,437,631; 5,591,205; 5,830,130; 5,868,778; 5,948,425; 6,017,359; and 6,090,130. In each of these patents, bioabsorbable, thrombogenic plugs comprising collagen and other materials are placed proximal to the vessel wall puncture site to stop bleeding. The large hemostasis plug stimulates blood coagulation in the vessel puncture site, but blocks the catheter entry tract, making catheter reentry more difficult, if required.

Other related prior art disclosed in U.S. Pat. Nos. 5,707,393; 5,810,884; 5,649,959; and 5,350,399 provides for the use of small dissolvable disks or anchors that are placed in the vessel to block or clamp the puncture hole. However, any device remaining in the vessel lumen increases the risk of thrombus formation. Such a device also can detach and cause occlusion in a distal blood vessel, which would likely require major surgery to remove.

Additional prior art includes U.S. Pat. Nos. 5,779,719; 5,496,332; 5,810,850; and 5,868,762. In the disclosure of these patents, needles and sutures delivered through catheters are used to ligate the puncture. The suturing procedure requires particular skill. Suture material left in the vessel may cause tissue irritation that will prolong the healing process.

Still other prior art is disclosed in U.S. Pat. No. 5,626,601, wherein a procoagulant is injected into the puncture, with a balloon catheter blocking inside the vessel lumen. However, in some cases, the clotting agent may leak past the balloon into the vessel lumen and cause stenosis.

Yet other prior art references related to this topic include U.S. Pat. Nos. 4,929,246; 5,810,810; and 5,415,657, which disclose the use of a laser or of radio-frequency (RF) energy that is transmitted to the blood vessel through a catheter to thermally fuse or weld the punctured tissue together.

All of the above cited prior art references require either introducing and leaving foreign objects in the patient's body, and/or inserting a tubular probe of large diameter into the tissue channel left by the catheter in order to seal the puncture.

As will be evident from the preceding discussion, there is a clear need for an improved method and apparatus for sealing a puncture left in a blood vessel, following an intravascular catheterization procedure. The method and apparatus should cause rapid cessation of bleeding, not rely on blood clot formation, and should be independent of the patient's coagulation status. By employing such a method and apparatus, the patient will be more comfortable as a result of shortened hemostasis and ambulation times, and physician and hospital resources will thereby be minimized. In addition, the method and apparatus should not leave any foreign object in the patient's body, to reduce the risk of stenosis at or distal to the puncture wound. An ideal device will be noninvasive and should not include any component that must be inserted in the catheter tract and which might further damage the wound and impede the sealing process.

SUMMARY OF THE INVENTION

In accord with the present invention, a method and apparatus are defined that provide advantageous solutions to the

problem of expeditiously and safely sealing vascular catheter entry wounds made in connection with medical procedures. The method includes the steps of determining a site of the puncture in the vascular vessel and positioning an ultrasonic transducer applicator at a position adjacent to the site. The ultrasonic transducer applicator is coupled to a control that includes a processor programmed to administer ultrasonic energy in a manner that efficaciously seals a puncture. A user is enabled to initiate a process that is controlled by the control, so that very little operator training is required. The control automatically controls the ultrasonic transducer applicator so that the ultrasonic energy produced by the ultrasonic transducer applicator is focused at the site and is administered at a sufficient intensity and duration to denature tissue at the puncture, closing and sealing the puncture.

To determine the site of the puncture, an imaging ultrasonic beam is generated with the ultrasonic transducer applicator and is transmitted into the patient, proximate an expected location for the site. A reflection of the imaging ultrasonic beam is then received from within the patient using the ultrasonic transducer applicator, producing a corresponding output signal. The output signal is processed with the processor included in the control to facilitate determining the site of the puncture.

For example, a visual indication of a location of the site of the puncture can be provided to enable an operator to position the ultrasonic transducer applicator so that the ultrasonic energy produced by the ultrasonic transducer applicator is directed at the site. Such a visual indication may be in the form of, for example, lighted display indicators. In one form of the present invention, the visual indication includes an image of the site in which an axis of the vascular vessel is visually evident, enabling the operator to position the ultrasonic transducer applicator longitudinally along the axis of the vascular vessel so that the ultrasonic energy is directed at the site of the puncture.

In an alternative embodiment, an object is provided that extends into the puncture from outside the patient. The operator can then estimate the location of the puncture along the longitudinal axis of the vessel based upon a disposition of the object extending outside the patient. As yet a further alternative, the visual indication includes an image of the site in which the object extending into the puncture is evident. An estimate is made of the location of the puncture based upon a disposition of the object in the image.

Finally, the output signal can be processed with the processor to determine the site of the puncture. An indicator disposed on the ultrasonic transducer applicator can be controlled by the processor to provide an indication of a direction in which the ultrasonic transducer applicator should be moved to position it adjacent to the site of the puncture.

The processor is preferably used for automatically controlling at least one of a direction, an intensity, and a focus of the ultrasonic energy, to ensure that the ultrasonic energy is administered to the site of the puncture. Using the processor, the ultrasonic energy is directed so as to overscan the site of the puncture, ensuring that the puncture is closed and sealed. For example, the processor can move the focus of the ultrasonic energy while it is being administered, to overscan the site of the puncture. As another alternative, an ultrasonic emitter of the ultrasonic transducer applicator has an aspheric shape so that the ultrasonic energy that is directed at the site of the puncture covers a larger area that overscans the site. Other transducer configurations that provide a laterally broadened focal region may also be employed.

Preferably, the ultrasonic transducer applicator uses a common array of transducers for generating both the imaging ultrasound beam and the ultrasound energy that closes and seals the puncture.

It is also contemplated that the administration of the ultrasonic energy be interrupted, to again generate the imaging ultrasound beam, thereby confirming whether the ultrasonic energy is being directed at the site of the puncture.

The processor is preferably employed to control a force applied against a surface of the patient using a force generator included in the ultrasonic transducer applicator. This force is controlled so that a pressure developed by the force is sufficient to substantially stop fluid leakage from the vascular vessel, but not so great as to substantially occlude fluid flow through the vascular vessel.

Another aspect of the invention is directed to enclosing the unit applicator within a protective, acoustic coupling shell. The protective, acoustic coupling shell is adapted to contact an external dermal portion of the patient in order to convey the ultrasonic energy transdermally to the site of the puncture, while isolating an ultrasonic emitter surface on the ultrasonic transducer from direct, contacting exposure to the patient. The protective, acoustic coupling shell is preferably pre-sterilized and preferably includes a gel patch on an outer surface that is protected by a tab. The tab is removed prior to contacting the external dermal surface of the patient.

Still another aspect of the present invention is directed to apparatus. The apparatus include elements that carry out functions generally consistent with the steps of the method discussed above.

BRIEF DESCRIPTION OF THE DRAWING FIGURES

The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same becomes better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:

FIG. 1 is a schematic block diagram of the primary components employed in a preferred embodiment of the present invention;

FIG. 2 is a schematic diagram illustrating how the present invention is employed for sealing a puncture in a vessel;

FIG. 3 schematically illustrates a collagen seal produced by the present invention to close the puncture in the vessel of FIG. 2;

FIG. 4 is a flow chart illustrating the logical steps followed during sealing of a vascular wound in accord with the present invention;

FIG. 4A is a flow chart illustrating the optional steps employed for detecting nerves during the method of FIG. 4;

FIG. 5 is a cross-sectional view of a portion of a patient's body, illustrating an applicator unit in accord with the present invention disposed adjacent to a puncture that extends transdermally into an artery;

FIG. 6 is a cutaway isometric view of the applicator shown in FIG. 5;

FIG. 6A is an isometric view showing the force sensing transducer, force generator, and ultrasonic array of the applicator;

FIG. 7 is an elevational view of a locator rod adapted to be inserted into a puncture wound over a guide wire;

FIG. 7A is a cross-sectional view of a portion of a patient's body like that in FIG. 5, illustrating the locator rod of FIG. 7 being used to determine a location of a puncture in the artery relative to the applicator unit;

FIG. 7B is similar to FIG. 7A, but illustrates the use of ultrasonic pulse-echo techniques to determine the spatial location of the locator rod;

FIG. 7C depicts a view of a framed two-dimensional image a target region generally orthogonal to that shown in FIG. 7A and FIG. 7B, for use in locating the puncture site;

FIG. 8 is a schematic isometric view of an embodiment of the applicator that uses a disposable shell;

FIG. 8A is an side view of the disposable shell of FIG. 8;

FIG. 9 is a schematic system block diagram depicting modules included in the applicator and control unit;

FIGS. 10 and 10A respectively illustrate the ultrasound beam orientation relative to the vessel from the side of the vessel and as viewed along the vessel;

FIG. 11 is a plan view of an embodiment of the applicator illustrating the controls and indicators that it includes;

FIGS. 12A and 12B respectively illustrate the side and longitudinal geometry of the therapeutic ultrasound beam; and

FIG. 13 is an isometric view illustrating the ultrasound beam geometry produced by an aspheric transducer.

DESCRIPTION OF THE PREFERRED EMBODIMENT

Use of Ultrasound for Sealing Punctures

Because of its unique properties in soft tissue, ultrasound can be brought to a tight focus at a distance from its source. If sufficient energy is radiated within the ultrasound beam, cells located in the focal volume can be rapidly heated, while intervening and surrounding tissues are spared. Surrounding tissues are unaffected in the unfocused portion of the ultrasound beam because the energy is spread over a correspondingly larger area and associated heating is minimized.

Whereas ultrasound intensities on the order of 0.1 Watts/cm² are employed in diagnostic imaging applications, intensities in excess of 1,000 Watts/cm² are typical in high-intensity focused ultrasound (HIFU) applications. At the focal point, these high intensities result in large, controlled temperature rises within a matter of seconds.

It has been demonstrated in numerous *in vivo* animal studies that HIFU can rapidly seal blood vessel punctures and lacerations over a wide range of sizes. When accurately targeted on a vascular wound, ultrasound has been shown to induce complete hemostasis in less than one minute in the femoral, carotid, and axillary arteries, and in the femoral and jugular veins of large animals, while blood flow through the treated vessels remained unaffected. These investigations included: (a) sealing punctured, surgically exposed vessels using visual targeting, (b) sealing incised, surgically exposed vessels using visual targeting, (c) sealing surgically exposed, punctured vessels using Doppler-guided ultrasound targeting, and (d) noninvasive sealing of punctured vessels under ultrasound imaging guidance wherein complete hemostasis was noted in 13±12 seconds.

The mechanism of hemostasis in these ultrasound-exposed vascular wounds appears thermal in origin and involves denaturation of native perivascular collagen with subsequent formation of an extensive fibrin network that covers the hole, thereby sealing it closed. The fibrin links with adjacent vessel wall tissues to form a seal that has been shown to be independent of puncture hole size. Acoustic streaming forces generated by the HIFU beam were also observed to play a role in opposing the escape of blood from the vascular wound. Blood clotting is not believed to be a factor in achieving acoustic hemostasis, as evidenced by equally rapid and complete

wound sealing in highly anticoagulated animals and *in vivo* vessels in which saline has been substituted for blood. Overview of the Present Invention

FIGS. 1 and 2 show the main components of an ultrasonic system suitable for use in implementing the present invention. As illustrated in FIG. 1, a hand-held applicator unit 2 is positioned over an arterial wound 8 in the patient. Included with the hand-held applicator unit is a generally single-use, pre-sterilized cover and acoustic coupling shell 4 that slips over applicator 2. A control unit 6 implements algorithms to facilitate the method and is coupled to applicator 2.

The user enters various conventional scan and control parameters into an input unit 70, which typically includes user input devices 72. Examples of such devices include a keyboard, knobs, and buttons. The input unit is connected to a processing system 74, which will typically comprise a plurality of microprocessors and/or digital signal processors. Processing system 74 may, however, also be implemented using a single processor of sufficient speed to handle the various tasks described below. A conventional memory 75 will normally be included in the system to store, among other data, transmission control parameters and imaging data generated in any given implementation of the present invention.

Processing system 74 sets, adjusts, and monitors the operating parameters of a conventional transmission and control circuit 76. Control circuit 76 forms a transmit ultrasonic waveform by generating and applying electrical control and driving signals to an ultrasound transducer 78, which preferably comprises an array of individually controllable piezoelectric elements. As is well known in the art, the piezoelectric elements generate ultrasonic waves when electric signals of a proper frequency are applied to them; conversely, when receiving reflected ultrasonic waves, they generate electrical signals corresponding to the mechanical vibrations caused by the returning ultrasonic waves.

Transducer 78 is positioned against its portion 82 of the body of a patient, and by varying the phasing, amplitude, and timing of the driving signals for the transducer array elements, ultrasonic waves are focused to form a transmit beam 314 of high-intensity ultrasound.

In FIG. 2, open arrows indicate the direction of a flow of blood within a blood vessel 312, which has a puncture site 316 that may have been caused by introduction of a catheter or, in the case of unintended punctures that have produced wounds, by some other object. The tissue forming a layer 318 of collagen found on the surface of blood vessels is also shown in FIG. 2 surrounding blood vessel 312.

As will be clear from the description of the present invention below, it is not necessary for the system to include an imaging capability. However, the provision of an imaging capability, including pulse-echo lines of interrogation that are not displayed as images, in the present invention should assist a user to more accurately locate a vascular puncture site. It is recognized that a full display of the insonified vascular target site is not required.

Nonetheless, since imaging of a vascular target site is preferable and will employ echo processing (especially, Doppler), FIG. 2 also illustrates a reception controller 88, which will include conventional amplification and signal conditioning circuitry as needed. Reception controller 88, all or part of which is normally integrated into processing system 74, converts the ultrasonic echo signals (which are typically at radio frequencies, on the order of a few to tens of megahertz) into lower frequency ranges for processing and may also include analog-to-digital conversion circuitry. The processing includes, as needed, such known signal conditioning as time-gating, gain compensation, Doppler frequency shift process-

ing, and diffraction compensation, in order to identify echo signals from any selected focal region. The type of conventional signal processing needed (if any) will in general depend on the particular implementation of the present invention employed and can be implemented using known design methods.

Note that it is not essential, according to the present invention, that the transducer **78** be used externally, relative to the patient's body. It is also contemplated that the transducer may be maneuvered inside a patient's body, and the beam focused on a puncture from inside the body. For example, a transeosophageal probe, laparoscopic, or other probe inserted into a body cavity, such as the vagina or rectum can be used to practice the present invention. A suitably designed probe inserted into an open body cavity or via minimally invasive means could be used to arrest bleeding in surgical or trauma care situations. Yet, most of the following discussion is directed to a preferred embodiment of the present invention in which the transducer is intended to be used externally, since an initial commercial product in accord with the present invention will be designed for such use.

A conventional display system **92** may also be included in order to display information concerning transmission power, time, focus data, etc. The display system will include known circuitry for scan conversion and for driving the display, as needed. These circuits are well known and therefore need not be specifically illustrated or described further to provide an enabling disclosure.

FIG. **3** illustrates the result of an insonification of puncture site **316** using the present invention. As the focal point of transmit beam **314** (see FIG. **2**) is moved around (as illustrated by the arrows pointing in either direction from the focus of the beam) the area of puncture site **316** using conventional beam-steering techniques, the tissue adjacent the puncture site **316** will denature. In effect, the collagen in the tissue "melts" and flows over and into the puncture opening. When the collagen cools, it forms a "patch" that not only covers the puncture, but also flows partially into the puncture opening in the wall of the blood vessel. Moreover, since the denatured tissue tends to contract, it also tends to pull the edges of the puncture together and thus further close the wound.

It should be noted that the present invention can be employed to seal vascular wounds of various types and is not limited to the type of wound created as a result of interventional procedures in which a catheter has been introduced into a vascular vessel. As noted above, application of thermal treatment to the tissue overlying a wound has been demonstrated to seal the wound. In the present invention, a practical method has been developed for repeatedly and reliably achieving sealing of the puncture in a vascular vessel.

Steps carried out in this method are shown in FIG. **4**, which is discussed below. These steps represent one preferred embodiment of the present invention, but do not represent all alternatives that might be employed to achieve acceptable sealing.

Key steps in the method for vascular sealing described here include:

1. Positioning an ultrasound generating source on a patient such that the source is targeted at an area including the wound to be sealed;
2. Applying a pressure against the patient in an area overlying the wound and directed substantially toward the vessel to be treated;
3. While the pressure and the positioning of the ultrasound source are maintained, carrying out an insonification of a volume of tissue that includes the wound, using an ultrasound exposure that delivers an acoustic energy

density (measured at the approximate location of the wound), in excess of 100 joules/sq. cm, but generally less than several thousand joules/sq. cm.

Additional steps of the method described below employ the apparatus in an automated manner that facilitates ease of use and ensures the safety and consistency of the results obtained.

A clinically acceptable device for sealing a puncture wound in accord with the present invention must meet a number of requirements, including:

1. The device and associated procedure must be safe to use in that they avoid undesirable bioeffects, so that the patient is not injured directly or indirectly as a result of the procedure; also, in the event that effective vessel sealing does not occur as desired, traditional methods of applying pressure to the wound are sufficient to accomplish hemostasis;
2. The device and associated procedure must be easy to use in an efficient manner, to facilitate proper, repeatable execution of the sealing process; requirements for operator training should be minimized;
3. The sealing process must be sufficiently fast to enable the entire procedure to be rapidly completed—preferably, in less than 5 minutes;
4. The cost per sealing procedure should be minimized; and,
5. The efficacy of the device should be very high, generally achieving a success rate in excess of about 95%; acceptability of the present invention in routine clinical practice does not permit an unpredictable outcome.

These requirements are met by the present invention, as described below, and as defined in the claims that follow. A preferred embodiment of the device includes the components shown in FIGS. **1** and **2**, which were described above.

FIG. **6** and FIG. **6A** show one preferred embodiment of applicator unit **2**. The applicator unit includes an outer housing **10** having an ergonomically considered shape so that it can be conveniently hand held. The outer housing is best fabricated from an injection moldable plastic material such as ABS or the like. The operator grasps the outer housing of the applicator unit so as to enable a control push-button **14** to be accessible and indicators **12**, **16** and **30**, **32**, **34**, and **36** to be visible to the operator. Positioning the applicator unit at the appropriate location over the wound area and activation of an essentially automated treatment cycle are readily accomplished. The operator simply refers to the indicators to determine when the applicator unit is properly positioned and ready for use. Indicators **12** and **16** are used to indicate when alignment of the applicator unit with the longitudinal axis of the vessel to be sealed has been achieved. Indicators **30**, **32**, **34**, and **36** display the state of operation and instruct the operator with respect to holding the applicator in place as described in detail later in this description. Control **14** when pressed, activates the treatment cycle, thus initiating a sequence of operations that determine ultrasonic scan parameters (exposure time, scan pattern, intensity, focal range, etc.).

As shown in FIG. **6A**, ultrasonic array assembly **20** is held within outer housing **10** on a shaft **40**, in a bearing assembly within a force transducer **18**, so as to permit movement of the ultrasonic array assembly to and away from patient **8**. Shaft **40** passes through the bearing assembly provided within a force generator **18** and terminates at a contacting force sensing transducer **42**. Force generator **18** comprises an electromagnetic solenoid that is rigidly supported and mounted within housing **10** by structural members **46**. The face of ultrasonic array assembly **20** is in contact with the appropriate location on the body of the patient (overlying the site of the puncture) and is thus capable of applying a substantially

compressive, controllable force on the tissue structures with which it is in contact. The force applied by the ultrasonic array assembly is produced at least in part by controllably energizing force generator 18. Ultrasonic array assembly 20 preferably operates in a multiplicity of modes; however, separate ultrasonic transducers can instead be provided for some or all of the functions performed in a different design within the scope of the present invention.

In the illustrated preferred embodiment, electrical connections comprising wires 26 are routed within the outer housing 10 and out in a sealed bushing 44 that mounts a cable 28 to the control unit 6. Cable 28 is sufficiently long, on the order of 10 feet in length, so that the control unit may be conveniently located at a distance from the patient and operator location.

Applicator unit housing 10 is shaped to be used with a slip-on, generally single-use protective applicator shell 4 (illustrated schematically in FIG. 1). The shell employed in the preferred embodiment is shown in greater detail in FIGS. 8 and 8A. Shell 4 has side walls 54 that are fabricated from a generally optically transparent, semi-rigid plastic material. A skirt 52 extends from the rear of the shell and is pleated so that in preparing for use of the applicator unit, an operator can grasp the skirt and extend it sufficiently to protect a sterile area of the patient from coming into contact with cord. The protective shell is packaged in a sterile condition. The shell is fabricated from a flexible plastic material having low acoustic absorption characteristics. A fiducial mark 56 is provided on a side of the applicator unit and visible through the optically transparent material of the protective shell. This fiducial mark is employed to visually align the applicator unit with a position on the patient at which the applicator unit will be used to seal a puncture.

Sterile, generally gas free acoustic coupling gel 62 is deposited in a patch on the bottom of flexible bottom 58. Prior to use, the gel is held in place and sealed by semi-sticky adhesive coated tab 60. Tab 60 is removed by the operator just prior to use, thereby exposing the gel so that it provides a good acoustic coupling with the surface of the patient's body. Protective applicator shell 4 thus provides a sterile barrier over the multi-use applicator unit and conveniently provides a pre-determined amount of a specific appropriate acoustic coupling medium. Although not shown, it is contemplated that the bottom of the interior cavity of the shell may also include a layer of acoustic coupling gel to ensure good acoustic coupling between the applicator unit through the protective, applicator coupling shell.

With reference to FIG. 1, applicator unit 2 is connected to control unit 6. Power supplies, signal processing components, and control and RF power generation components are housed within control unit 6. FIG. 9 is a system block diagram illustrating the modules disposed, in the preferred embodiment, within the applicator unit 2 (i.e., the component shown within the dotted line portion of this Figure) as well as the modules (all other modules that are not in the applicator unit) disposed in the control unit 6. In this preferred embodiment, control unit 6 is packaged in a small, self-contained pole- or cart-mounted enclosure that derives its input power from a standard AC line power service (not shown). Power supplies with the unit are designed to assure low leakage currents for patient safe operation.

In the preferred embodiment the architecture of control unit 6 is based on a programmable processing unit which processes various signals and controls a number of functional modules. A microprocessor is well suited to perform the computation and control functions required. Applicator unit 2 is coupled to control unit 6 by a plurality of signal paths 212, 214, 216, and 218. Signal path 212 couples display drivers

200, which are controlled by a computer/controller 236, with indicators 30, 32, 34, and 36 on the applicator unit. Control button 14 on the applicator unit is coupled through signal line 214 to an interface 202 and thus to the computer/controller. Force sensing transducer 42 produces an output signal indicative of the force (i.e., the pressure) applied against the surface of the patient's tissues by the applicator unit, and this signal is conveyed by signal lines 216 to an interface 204, which provides the signal to the computer/controller. In response to the magnitude of the monitored force, the computer/controller produces a control signal applied to a driver 206, which provides the current signal used to energize force transducer 16, to determine any additional force that it generates to achieve a desired pressure on the site of the puncture that is sufficient to prevent loss of fluid from the vessel, but not so great as to occlude the flow of fluid through the vessel.

Signal lines 240 couple ultrasonic array assembly 20 to a transmit/receive switch 224. The transmit/receive switch determines the operational mode of the ultrasonic array assembly under the control of the computer/controller. When operating in a diagnostic mode in which the ultrasonic array assembly is producing an imaging ultrasound beam, the signal corresponding to the echo reflected received by ultrasonic array assembly 20 from tissue and other structures is conveyed through transmit/receive switch 224 and through signal lines 222 to an amplifier digitizer array 220. The output signals from the amplifier digitizer array are conveyed to computer/controller 236 through signal lines 228. When the ultrasonic array assembly is generating either the imaging beam or the HIFU beam, it is responding to signals received from an RF generator 232 that is coupled to a phase shift/amplifier array 234 by signal lines 236, and to a control signal provided by the computer/controller and conveyed to the phase shift/amplifier on a signal line 230. The output of the phase shift/amplifier is conveyed on signal lines 226 to transmit/receive switch 224, and thus, to ultrasonic array assembly 20 through signal lines 240. Manual control inputs 241 are coupled to computer/controller 236 through signal lines 242.

A number of variously advantageous transducer configurations may alternatively be employed in this invention. Possibilities include:

- Configurations wherein therapeutic and, pulse-echo Doppler functionality are accomplished by the same ultrasonic transducer or by separate ultrasonic transducers; and,
- Configurations wherein the ultrasonic transducer is either of a fixed focus type, or a segmented electrically selectable macro element array, or a phased array, or a linear array, or an annular array; and,
- Configurations where a large focal spot 412 (see FIG. 13) (e.g. a focal spot produced by a transducer having an aspheric shape), or those in which a tightly focused spot is produced; and,
- Configurations wherein the ultrasonic transducer is mechanically positioned (or scanned), or those in which it is fixed in one position.

An aspheric ultrasonic transducer configuration has the advantage of covering a large treatment area on the surface of the vessel without the complication of electronic or mechanical beam steering. Covering a large area (i.e., overscanning) is desired in order to ensure that the actual site of the puncture wound is treated, given its positional ambiguity. FIG. 13 depicts the geometry of such a configuration. In this embodiment, an ultrasonic transducer 404, excited by an appropriate RF source via connections 402, is generally aspheric in shape and does not bring the ultrasound beam to a sharp focus. The ultrasonic energy that it produces covers area 412 on a vessel

408 that includes puncture wound 410. Fluid or solid material acoustic coupling (not shown) is used between the ultrasonic transducer and the tissues of the patient.

In one preferred embodiment, the method described includes a series of manual steps (operator actions) and automated steps. The automated steps are carried out as control processes or algorithms executed by one or more processors and other hardware in accord with machine instructions executed by the one or more processors. It is understood that variations in the order of these steps, and in the total complement of steps implemented is possible in alternative embodiments. Steps as shown in FIG. 4 are described as follows.

In a step 100 labeled Patient Preparation, the operator positions the patient and the apparatus so that the applicator unit is conveniently positioned over the puncture wound area, e.g., over the puncture made by a catheter in the femoral artery. Shell 4 is removed from its sterile package and fitted onto applicator unit 2, and gel sealing tab 60 (shown in FIGS. 8 and 8A) is removed, exposing the gel 62.

A step 102 labeled Manually Align is then carried out. With the catheter introducer in the wound, the operator palpates the area locating the point at which the introducer just enters the artery. The operator marks this location on the patient's skin with a suitable marking device (e.g. a surgical marker), drawing a line substantially perpendicular to the perceived direction of the artery, extending approximately 3 cm from the entry wound location. It is the purpose of this marking to estimate the longitudinal location of the wound; the operation of the HIFU sealing process provides for an overscan of the wound area so that practical variations in the operator's ability to make the longitudinal position estimate are permissible. Other techniques for locating the site of the puncture are discussed below. In a more preferred embodiment, lateral and range locations of the wound are more precisely located by the automated capability of the processor(s) used in the apparatus.

Also within step 102, the operator places the device over the wound location, aligning fiducial mark "56" (shown in FIG. 8) with the line that was drawn on the patient's skin. The applicator unit is rotated in place until both alignment indicators 12 and 16 (FIGS. 6 and 8) illuminate, indicating that the artery is axially aligned under the applicator unit.

The axial alignment indications are, in this preferred embodiment, derived from two ultrasonic pulsed Doppler interrogations. FIGS. 10 and 10A show the geometry of the Doppler alignment beams. Use of a ultrasonic transducer 20 enables the same ultrasonic transducer to be employed to produce an imaging beam and the HIFU beam for both a pulse-echo targeting mode and a therapeutic mode.

In the alignment sequence illustrated in FIGS. 10 and 10A, phased array ultrasonic transducer 20 sends and receives a downstream pulsed Doppler line 304 and an upstream line 308 sequentially. Lines 304 and 308 are in plane with the axial centerline of the applicator unit and a line perpendicular to the bottom surface of the applicator unit. Lines 304 and 308 are transmitted at angles A and B with respect to a line 306, which is perpendicular to the applicator unit. Angles A and B are chosen to provide a axial separation as well as an appreciable vector flow component in the direction of the interrogating line—an angle of approximately 45 degrees. Direction of flow in an interior 310 of the vessel is sensed and tested to assure that an artery 300 (not a vein) is being interrogated. Doppler signals, from lines 304 and 308, integrated over an appropriate range, above a pre-determined threshold value, are used to cause the illumination of alignment indicators 12 and 16 respectively. Averaging multiple lines is, in this preferred embodiment, employed to improve the performance of

the alignment detection scheme. The conditioned signals also set logical flags so that the system may interlock the initiation of a therapeutic treatment sequence with assurance of alignment. Thus in a decision step 106 (FIG. 4), alignment is tested by interrogating the logical presence of both of the flags.

Alternatively, another advantageous configuration for guiding the manual alignment process uses multiple Doppler lines and multiple indicators, with reference to FIG. 11, which illustrates a top view of the applicator unit. In this configuration, three parallel lines are transmitted and received in the two directions indicated by lines 304 and 308 in FIG. 10. Additional transducers are appropriately positioned in housing 10 (FIG. 6). Pulsed Doppler signals are processed in a manner similar to that described above. Thus, for example (referring to FIG. 11), if the alignment is off-center and rotated to the left, indicator lights 336 and 334 would be illuminated, indicating the misalignment and suggesting the appropriate direction to move the applicator unit to achieve alignment (denoted when indicators 338 and 330 are illuminated). Alternatively, continuous wave Doppler may be employed to interrogate the flow position of the target artery, with operation essentially similar to that described above.

With verified alignment in step 106, the system proceeds to a step 108 labeled Set Pressure, wherein the pressure over the artery is set and controlled within a predetermined range using force generator 18 (FIG. 6) and force sensing transducer 42. In this preferred embodiment, the weight of the applicator unit is purposefully made to be in a range where additional pressure applied by the operator to hold the unit firmly in place is reduced. This useful weight is about 1 lb (0.45 kg) or more. Force generator 18 is activated and controlled such that applied pressure to the artery partially restricts flow, but maintains sufficient flow so that thermal cooling due to blood flow within the artery protects the intimal lining of the vessel from irreversible damage. Presence of a Doppler flow signal on down-stream line 304 (FIG. 10) is employed to assure vessel patency.

In this preferred embodiment, when the system has completed the pressure application cycle described above, indicator 32 (FIG. 6), which is marked "READY" on the applicator unit is illuminated (see block 118 FIG. 4), indicating to the operator that a treatment cycle may be manually initiated (triggered) by pushing control button 14. The system is in a wait state as indicated in a decision block 112 in FIG. 4, until a manually triggered treatment cycle is detected. With the detection of a triggered treatment cycle, axial alignment is verified in a step 114 by generally repeating the logical test described at step 102.

A step 116 then makes a ranging measurement to estimate the acoustic path length between ultrasonic transducer assembly 20 and the vessel boundary. i.e. the distance between points F and C along line 306 in FIG. 10. Pulsed Doppler is, in this preferred embodiment, employed to make this measurement, wherein lines 304 and 308 measure distances F-D and F-E, respectively. Points D and E are recognized by the fact that these correspond to the first instance of flow detected along each line as range increases. The range estimate of FC is therefore:

$$FC = (FE \cos A + FD \cos B) / 2 \quad \text{Equation 1}$$

A step 120 estimates the acoustic attenuation at the therapeutic frequency between ultrasonic transducer assembly 20 and the target collagen layer overlaying the vascular wound, path F-C in FIG. 10. In this preferred embodiment, a simplified approach is employed wherein estimated dimension FC is used to access data in a look-up table of attenuation values.

Attenuation values in the table are predetermined by empirical measurement. Alternatively, more sophisticated A-Mode attenuation measurements may be employed to assess to F-C path.

A step 122 determines the therapeutic ultrasound exposure parameters to be employed. Dimension F-C, the attenuation estimate, and optionally, patient parameters (e.g., size and weight), input at module 240 in FIG. 9, are used to access predetermined data and scan protocols in resident look-up tables. Ultrasound scan geometry, intensity and epochal exposure intervals are thus determined.

Ultrasound scan geometry, intensity and time parameters are determined to accomplish three key objectives: (1) provide a sufficient overscan of a longitudinal and lateral surface of the target vessel so as to include the site of the wound; (2) ensure delivery of an appropriate energy dose to the collagen layer in the region of the target site to raise its temperature to a range of between 60 and 100 degrees Celsius for a predetermined period of time; and, (3) assure that the skin and interpath tissue is not exposed to a temperature-time exposure that will result in pain and or irreversible tissue damage.

Therapeutic scan geometry is shown in FIGS. 12A and 12B. A therapeutic level of approximately 50 watts total transmitted acoustic power, generally weakly focused, is transmitted along a centerline 314 through a dermal layer 302. The desired scan pattern is achieved by directing the beam over varying angles of the beam with respect to a line 320 that extends perpendicular to the center of the face of the application unit. Thus, for example, a raster scan pattern may cover a therapeutic area, over collagen layer 318, of dimensions 1 cm wide by 1.5 cm long (in the arterial axial direction). Such an overscan of the wound site provides for variations in the operator's ability to predetermine and locate the precise lateral position of the wound, as well as the variation in wound location that results from the possible variation of wound lateral entry points. Importantly, scan geometry is selected such that ultrasonic exposure is generally confined to the vessel, minimizing the possibility that an adjacent vein or nerve structure will be insonified.

A step 126 carries out the therapeutic exposure cycle. It is generally desirable to hold the applicator unit in place, providing the established orientation and pressure for a period of time after the therapeutic exposure cycle. A hold interval 130 (FIG. 4) is selected to enable exposed tissue structures to cool, a time period of approximately 1 minute. Following this time period, indicator 36 on the application unit (FIG. 6) marked "COMPLETE" is illuminated and the "HOLD" indicator is turned off, instructing the operator that the therapeutic treatment is completed and the device may be removed from the patient.

In situations where there is concern for inadvertent exposure of a nerve structure, an additional sequence depicted in FIG. 4A may optionally be employed. The sequence is inserted into the process flow of FIG. 4, in this preferred embodiment, at a location marked "A." To detect the presence of a nerve structure, a weak, sub-therapeutic energy level ultrasonic pulse is transmitted in a step 136 (FIG. 4A), to cover the determined target area. The operator observes in a decision step 138 whether a reaction of pain and or uncommanded movement from the patient has occurred, indicating that a nerve structure has been stimulated. System logic then waits for an addition manually initiated trigger input in steps 140 and 142, prior to proceeding with therapeutic exposure at step 126 in FIG. 4.

Alternative Techniques for Aligning the Applicator Unit

Step 102, which facilitates alignment of the applicator unit over the wound area and targeting of the therapeutic expo-

sure, may be accomplished using several alternative approaches compared to that described above. It is desired to employ an approach for targeting and aligning the applicator unit that is easy to implement and requires minimum operator instruction. The approach further should be consistent with minimizing bleeding during the process of achieving alignment. Additionally, the approach should be robust and provide targeting of the wound site with sufficient accuracy such that the wound will reliably be included within the area of therapeutic exposure.

A principle employed in the present invention is the concept that the overscan of the target location during therapeutic exposure is sufficient to accommodate targeting ambiguity and possible patient or operator movement during the procedure. Nevertheless, accurate targeting is needed to ensure efficacy of the wound sealing process.

In the preferred embodiment described above, pulsed Doppler ranging was employed to locate the axis of the vessel, and the operator was advised of the longitudinal location of the wound on the vessel by reference to visual landmarks on the skin surface. Alternatively, by inclusion of additional automation, the need for the operator to locate the longitudinal position is eliminated, thereby substantially simplifying the targeting procedure for the operator.

These alternative approaches make use of the entry channel along which the introducer and guide wire are commonly passed during diagnostic and interventional catheterization procedures. FIG. 5 illustrates the geometry that relates the location of applicator unit 2 to the locations of an entry channel 518 and a vessel wound 516. In FIG. 5, applicator unit 2 is positioned on a patient's skin surface 510 over a vessel 506 in which a blood flow 508 is contained. A location "C" is indicated at wound 516; a line 512 passes from "C" through entry channel 518, intersecting a plane 514 defined by reference locations on applicator unit 2 at a point "H." A point "F" is a reference point in plane 514. If the spatial location of line 512 is known relative to plane 514 and point "F," and the vector distances "H" to "F", or "C" to "F" are known, then the location of wound 516 relative to applicator unit 2 is determinable by basic geometry. Knowledge of this geometry permits automated system function to be employed to provide guidance instructions (e.g. visual indicators) to the operator during the manual alignment portion of the procedure.

A sufficient number of the parameters in the above described geometry may be determined by several novel methods and their associated apparatus. As previously described, acoustic pulsed Doppler may be employed to determine the distance "C"- "F" (reference FIG. 5). In many applications of the vascular sealing method described herein, the vessel is an artery having a substantial high velocity flow and is thus readily localized using well known pulsed Doppler techniques. Knowing this distance, localization of wound 516 on the vessel is made possible by determining the spatial position of line 512.

The spatial location of line 512 may be determined by employing a substantially rigid, straight locator rod 554 as depicted in FIG. 7, which is placed in entry channel 518. Locator rod may have a longitudinal center bore 556 through which a guide wire 552 may pass. In practical use, the introducer used in conjunction with a clinical procedure would be removed without removing the guide wire. Locator rod 554 would be introduced into the wound over the guide wire. Sealing assembly 550 is disposed at one end of the locator rod to prevent the loss of blood through center bore 556.

Several alternative approaches may be employed to determine the spatial location of the longitudinal axis of locator rod

554 and thus, to determine precise wound location as described above. These approaches include:

1. As shown in FIG. 7A, a spatial position resolving element 558 may be included on locator rod 554. Spatial position resolving element 558 may be an acoustic position sensor, an optical position sensor, a magnetic position sensor, an electromechanical positioning or resolving arm, or an inertial position sensor. The spatial relationship between the position of locator rod 554 and applicator unit 2 is accomplished by either a direct mechanical linkage or by way of an intermediate electronic or computational circuit.
2. As shown in FIG. 7B, an ultrasonic pulse-echo technique may be employed to determine the spatial location of locator rod 554. A transducer in applicator unit 2 transmits directed acoustic pulses in more than one direction, e.g., lines 560, 562, and 564, and echoes from structures in each path are returned and detected by a pulse-echo receiver included in the applicator unit, as is well known in the diagnostic ultrasound art. Locator rod 554 provides reflections that permit making time of flight measurements of, for example, distances "F"- "J," "F"- "K," and "F"- "L." Locator rod 554 may be coated or constructed of materials chosen to enhance acoustic reflectivity, thus providing echoes that are readily distinguished from background clutter. Common guide wires may alternatively be used as locator rod 554, as these wire structures are typically highly reflective of ultrasound energy. Alternatively, locator rod 554 may be constructed from materials that enhance reflection at a harmonic of the interrogating ultrasound pulse, providing another advantageous method for clearly distinguishing the echoes from locator rod 554 from those received from surrounding tissue. Materials or coatings that entrap gas bubbles are, for example, effective in providing higher harmonic reflection. Echo enhancing properties may also be incorporated into an introducer that is then used as the locator rod. Pulsed Doppler may also be employed to identify and locate the locator rod. In this latter alternative, the locator rod may be a common introducer. A strong Doppler shifted reflection will return from the lumen of the introducer even when blood is not permitted to flow out of the introducer.
3. As indicated in FIG. 7C, two dimensional, or three dimensional, imaging may also be employed to locate locator rod 554, the guide wire, and the introducer, as well as the vessel. FIG. 7C depicts a view of a framed two-dimensional image 580 of the target region generally orthogonal to that shown in FIGS. 7A and 7B. Distance from the ultrasound source increases toward the bottom of this depiction. This image is generally representative of a cross-sectional plane of interrogation located at a line 562 in FIG. 7B. Automated image recognition provided by the processor may be employed to identify structures including locator rod 554, imaged as a locator rod structure 586 and vessel 506, imaged as a vessel structure 584 in this image. Doppler imaging and color flow mapping may be employed to increase the recognizability of relevant features. The interrogating image plane may be scanned over the region containing the target. When locator rod structure 586 is recognized at a location just touching the top surface of vessel structure 584, the wound target site has been identified.

Although the present invention has been described in connection with the preferred form of practicing it, those of ordinary skill in the art will understand that many modifications can be made thereto within the scope of the claims that

follow. Accordingly, it is not intended that the scope of the invention in any way be limited by the above description, but instead be determined entirely by reference to the claims that follow.

What is claimed is:

1. A method for determining exposure parameters for a high intensity focused ultrasound system used to noninvasively target a blood vessel in a patient with a high intensity focused ultrasound beam, the method comprising:
 - providing the high intensity focused ultrasound system including at least one ultrasound transducer having a plurality of transducer elements
 - imaging the blood vessel to be treated with the high intensity focused ultrasound beam;
 - identifying tissue along an ultrasound energy path through which there will be a subsequent application of ultrasound energy between the blood vessel and the at least one ultrasound transducer;
 - estimating high intensity ultrasound energy intensities at the blood vessel and non-zero ultrasound energy intensities at the tissue for a subsequent application of high intensity focused ultrasound through the tissue to the blood vessel along the ultrasound energy path between the blood vessel and the at least one ultrasound transducer based at least in part on the relative position between the transducer(s) and the blood vessel and the relative position between the transducer(s) and the tissue along the ultrasound energy path between the blood vessel and the at least one ultrasound transducer; and
 - determining exposure parameters for the high intensity focused ultrasound beam that cause the estimated energy intensity delivered to the blood vessel to remain above a first level while the estimated energy intensity at the tissue along the ultrasound energy path between the blood vessel and the at least one ultrasound transducer remains below a second level, wherein the second level is less than the first level but greater than zero, wherein the exposure parameters include at least one of ultrasound intensity level, exposure interval, and scan geometry, and wherein the exposure parameters are determined to ensure that the second level will not result in irreversible damage to the tissue along the ultrasound energy path between the blood vessel and the at least one ultrasound transducer.
2. The method of claim 1, wherein the first level is sufficient to raise a temperature of the blood vessel to between about 60 and about 100 degrees Celsius.
3. The method of claim 1, further comprising treating the blood vessel with the high intensity focused ultrasound beam.
4. The method of claim 1, wherein the ultrasound transducer comprises a phased array of transducers.
5. A method for determining one or more operational parameters of a high intensity focused ultrasound system for a noninvasive therapeutic application of a high intensity focused ultrasound beam to a patient, the method comprising:
 - providing the high intensity focused ultrasound system including at least one transducer element;
 - imaging a blood vessel to be exposed with the high intensity focused ultrasound beam emitted from the high intensity focused ultrasound system;
 - estimating an acoustic path length between the transducer element(s) and the blood vessel;
 - estimating an acoustic attenuation value of the high intensity focused ultrasound beam propagated from a position external to the patient based at least in part on the acoustic path length and a look up table of attenuation values; and

- determining one or more operational parameters of the high intensity focused ultrasound system based at least in part on the acoustic attenuation value, wherein the parameters ensure that a dose of high intensity therapeutic energy is delivered from the high intensity focused ultrasound system to the blood vessel while assuring that interpath tissue is not exposed to an energy intensity that will result in tissue damage, wherein the operational parameters include at least one of ultrasound intensity level, exposure interval, and scan geometry.
6. The method of claim 5, wherein the dose of high intensity therapeutic energy causes a collagen layer in the blood vessel to reach a temperature of between about 60 degrees Celsius and about 100 degrees Celsius.
 7. The method of claim 5, wherein the estimating an acoustic attenuation value based at least in part on the acoustic path length step comprises employment of A-mode attenuation measurements.
 8. The method of claim 5, wherein the estimating an acoustic attenuation value based at least in part on the acoustic path length step comprises the use of a look table based on predetermined empirical measurements.
 9. The method of claim 5, wherein the blood vessel is identified through detecting a Doppler signal.
 10. The method of claim 5, further comprising an over-scan of the blood vessel to compensate for targeting ambiguity.
 11. The method of claim 5, wherein the blood vessel comprises collagen overlaying a vascular target.
 12. The method of claim 5, wherein the estimating an acoustic attenuation value based at least in part on the acoustic path length step is further based at least in part on patient weight.
 13. The method of claim 5, wherein pulse-echo lines of interrogation are utilized to assist in the identification of the target tissue.
 14. The method of claim 5, wherein the dose of high intensity therapeutic energy is sufficient to raise a temperature of the blood vessel to between about 60 and about 100 degrees Celsius.
 15. The method of claim 5, further comprising treating the blood vessel with the high intensity focused ultrasound beam.
 16. The method of claim 5, wherein the transducer element comprises a phased array of transducers.
 17. A method for determining one or more operational parameters of a high intensity focused ultrasound system for

- a noninvasive therapeutic application of a high intensity focused ultrasound beam to a vascular target, the method comprising:
- providing the high intensity focused ultrasound system including at least one transducer element;
 - utilizing imaging to identify the vascular target to be exposed with the high intensity focused ultrasound beam emitted from at least one of the transducer element(s);
 - estimating an acoustic path length between at least one of the transducer element(s) and the vascular target;
 - estimating an acoustic attenuation value of the high intensity focused ultrasound beam propagated from a position external to the patient based at least in part on the acoustic path length and a look up table of attenuation values; and
 - determining one or more operational parameters of the high intensity focused ultrasound system based at least in part on the acoustic attenuation value, wherein the parameters ensure that a dose of high intensity therapeutic energy is delivered from the high intensity focused ultrasound system to the vascular target while assuring that interpath tissue is not exposed to an energy intensity that will result in tissue damage, wherein the operational parameters include at least one of ultrasound intensity level, exposure interval, and scan geometry.
18. The method of claim 17, wherein the imaging comprises Doppler imaging.
 19. The method of claim 17, wherein the imaging comprises pulse-echo lines of interrogation.
 20. The method of claim 17, wherein the high intensity focused ultrasound system comprises an imaging transducer and a therapy transducer.
 21. The method of claim 20, wherein the imaging transducer is the same as the therapy transducer.
 22. The method of claim 17, wherein the dose of high intensity therapeutic energy is sufficient to raise a temperature of the vascular to between about 60 and about 100 degrees Celsius.
 23. The method of claim 17, further comprising treating the vascular target with the high intensity focused ultrasound beam.
 24. The method of claim 17, wherein the transducer element comprises a phased array of transducers.

* * * * *

专利名称(译)	用于聚焦超声应用的方法和设备		
公开(公告)号	US8388535	公开(公告)日	2013-03-05
申请号	US13/011533	申请日	2011-01-21
[标]申请(专利权)人(译)	翁LEE PEROZEK DAVID中号 张吉敏		
申请(专利权)人(译)	翁, LEE PEROZEK, DAVID M. 张, 济民		
当前申请(专利权)人(译)	KONA MEDICAL, INC.		
[标]发明人	WENG LEE PEROZEK DAVID M ZHANG JIMIN		
发明人	WENG, LEE PEROZEK, DAVID M. ZHANG, JIMIN		
IPC分类号	A61B8/00 A61B17/00 A61B17/12 A61B18/00 A61B19/00 A61N7/02 G10K11/32 G10K11/34		
CPC分类号	A61B8/4422 A61B17/0057 A61N7/02 G10K11/32 G10K11/346 A61B2017/00504 A61B2017/00641 A61B2017/00907 A61B2019/462 A61B2019/5276 A61B2019/5404 A61B2019/5437 A61B2562/164 A61B2090/062 A61B2090/378 A61B2090/3904 A61B2090/3937		
审查员(译)	基士JAMES		
优先权	09/696076 2003-12-02 US 60/163466 1999-10-25 US 60/171703 1999-12-23 US		
其他公开文献	US20110118602A1		
外部链接	Espacenet USPTO		

摘要(译)

超声波施加器单元 (2) 在诊断上用于将穿刺伤口 (316) 定位在动脉中, 然后在治疗上用高强度聚焦超声 (HIFU) 密封穿刺伤口。连接到施加器单元的控制单元 (6) 包括处理器 (74), 其自动化该过程, 控制诊断和治疗模式的各种参数, 包括施加器单元发射的超声能量的强度和持续时间。保护性无菌声学外壳 (4) 用于与单个患者一起使用然后丢弃, 在施用器单元上滑动以防止施用器单元与患者之间的直接接触并且保持在患者身处的无菌区域。穿刺的部位。该装置和方法特别适用于密封在将导管插入动脉或其他血管时制成的穿孔。描述了用于定位穿刺伤口的若干不同程序, 包括对其中设置穿刺的血管成像以及使用定位杆来确定穿刺沿着动脉的纵向轴线的布置。

